Balyasny Asset Management
TRVI icon

Balyasny Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Balyasny Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.65M Buy
473,849
+299,208
+171% +$3.35M 0.01% 1320
2025
Q4 		$2.19M Sell
174,641
-451,821
-72% -$5.22M ﹤0.01% 1806
2025
Q3 		$5.73M Sell
626,462
-1,727,940
-73% -$13M 0.01% 1308
2025
Q2 		$12.9M Buy
2,354,402
+595,783
+34% +$3.71M 0.02% 850
2025
Q1 		$11.1M Buy
+1,758,619
New +$8.39M 0.02% 861

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Balyasny Asset Management's TRVI Position: Q1 2026 in Review

Balyasny Asset Management increased its Trevi Therapeutics (TRVI) stake by 171% in Q1 2026, buying an estimated $3.35M and bringing the position to 473,849 shares worth $5.65M. The position accounts for 0.01% of the portfolio, ranked #1320.

Balyasny Asset Management first reported a position in TRVI in Q1 2025 and has held it in 5 quarters since. The position peaked at $12.9M in Q2 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Balyasny Asset Management held 473,849 shares of Trevi Therapeutics worth $5.65M as of Q1 2026.
  • Balyasny Asset Management bought 299,208 Trevi Therapeutics shares in Q1 2026, an estimated $3.35M.
  • Trevi Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1320 holding.
  • Balyasny Asset Management first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Balyasny Asset Management's Trevi Therapeutics position peaked at $12.9M in Q2 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.